Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells.

Literature DB >> 19646757

Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells.

Sarah A Holstein¹, Huaxiang Tong, Raymond J Hohl.

Abstract

Thalidomide has emerged as an effective agent for treating multiple myeloma, however the precise mechanism of action remains unknown. Agents known to target the isoprenoid biosynthetic pathway (IBP) can have cytotoxic effects in myeloma cells. The interactions between thalidomide and IBP inhibitors in human multiple myeloma cells were evaluated. Enhanced cytotoxicity and induction of apoptosis were observed in RPMI-8226 cells. Examination of intracellular levels of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) revealed a wide variance in basal levels and response to IBP inhibitors. These findings provide a mechanism for the differential sensitivity of myeloma cells to pharmacologic manipulation of the IBP. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2009 PMID： 19646757 PMCID： PMC4228479 DOI： 10.1016/j.leukres.2009.06.035

Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156

47 in total

1. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.

Authors: J E Dunford; K Thompson; F P Coxon; S P Luckman; F M Hahn; C D Poulter; F H Ebetino; M J Rogers
Journal: J Pharmacol Exp Ther Date: 2001-02 Impact factor: 4.030

2. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade.

Authors: A Ogata; D Chauhan; G Teoh; S P Treon; M Urashima; R L Schlossman; K C Anderson
Journal: J Immunol Date: 1997-09-01 Impact factor: 5.422

Review 3. Membrane association and targeting of prenylated Ras-like GTPases.

Authors: M C Seabra
Journal: Cell Signal Date: 1998-03 Impact factor: 4.315

4. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo.

Authors: E van Beek; E Pieterman; L Cohen; C Löwik; S Papapoulos
Journal: Biochem Biophys Res Commun Date: 1999-02-16 Impact factor: 3.575

5. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.

Authors: C M Shipman; P I Croucher; R G Russell; M H Helfrich; M J Rogers
Journal: Cancer Res Date: 1998-12-01 Impact factor: 12.701

6. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo.

Authors: D E Hughes; K R Wright; H L Uy; A Sasaki; T Yoneda; G D Roodman; G R Mundy; B F Boyce
Journal: J Bone Miner Res Date: 1995-10 Impact factor: 6.741

7. Thalidomide is an inhibitor of angiogenesis.

Authors: R J D'Amato; M S Loughnan; E Flynn; J Folkman
Journal: Proc Natl Acad Sci U S A Date: 1994-04-26 Impact factor: 11.205

8. Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells.

Authors: A Ogata; D Chauhan; M Urashima; G Teoh; S P Treon; K C Anderson
Journal: Clin Cancer Res Date: 1997-06 Impact factor: 12.531

9. Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6.

Authors: D Billadeau; D F Jelinek; N Shah; T W LeBien; B Van Ness
Journal: Cancer Res Date: 1995-08-15 Impact factor: 12.701

10. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl.

Authors: S J Martin; C P Reutelingsperger; A J McGahon; J A Rader; R C van Schie; D M LaFace; D R Green
Journal: J Exp Med Date: 1995-11-01 Impact factor: 14.307

9 in total

1. Pleiotropic effects of a schweinfurthin on isoprenoid homeostasis.

Authors: Sarah A Holstein; Craig H Kuder; Huaxiang Tong; Raymond J Hohl
Journal: Lipids Date: 2011-06-02 Impact factor: 1.880

Review 2. Isoprenoids, small GTPases and Alzheimer's disease.

Authors: Gero P Hooff; W Gibson Wood; Walter E Müller; Gunter P Eckert
Journal: Biochim Biophys Acta Date: 2010-04-08

3. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.

Authors: Gareth J Morgan; Faith E Davies; Walter M Gregory; Nigel H Russell; Sue E Bell; Alexander J Szubert; Nuria Navarro Coy; Gordon Cook; Sylvia Feyler; Jenny L Byrne; Huw Roddie; Claudius Rudin; Mark T Drayson; Roger G Owen; Fiona M Ross; Graham H Jackson; J Anthony Child
Journal: Blood Date: 2011-06-07 Impact factor: 22.113

4. Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis.

Authors: Jacqueline E Reilly; Jeffrey D Neighbors; Huaxiang Tong; Michael D Henry; Raymond J Hohl
Journal: Clin Exp Metastasis Date: 2015-06-13 Impact factor: 5.150

5. Modulation of cholesterol, farnesylpyrophosphate, and geranylgeranylpyrophosphate in neuroblastoma SH-SY5Y-APP695 cells: impact on amyloid beta-protein production.

Authors: Gero P Hooff; Imke Peters; W Gibson Wood; Walter E Müller; Gunter P Eckert
Journal: Mol Neurobiol Date: 2010-04-21 Impact factor: 5.590

6. Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells.

Authors: Sarah A Holstein; Raymond J Hohl
Journal: Leuk Res Date: 2010-09-09 Impact factor: 3.156